非典型抗精神病药物与神经性厌食症：综述。

Atypical antipsychotics and anorexia nervosa: a review.

机构信息

Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, UK.

出版信息

Eur Eat Disord Rev. 2010 Jan;18(1):10-21. doi: 10.1002/erv.988.

DOI:10.1002/erv.988

PMID:20054875

Abstract

BACKGROUND

There is currently mixed opinion regarding the value of using atypical antipsychotics to treat anorexia nervosa (AN).

AIMS

To evaluate the literature on the use of atypical antipsychotics in AN.

METHOD

A review of all studies and clinical guidelines published before September 2009 involving use of an atypical antipsychotic in patients with AN. Analysis is by narrative synthesis.

RESULTS

Forty-three publications or study protocols were found, including four randomized-controlled trials, five open-label trials and 26 case reports. The most studied drugs were olanzapine, quetiapine and risperidone. Atypical antipsychotics appear safe and there is some evidence of positive effects on depression, anxiety and core eating disordered psychopathology in patients with anorexia nervosa. Currently there is insufficient evidence to confirm atypical antipsychotics enhance weight gain in this setting.

CONCLUSIONS

Further high quality evidence is needed in this area in order to provide practical guidance to clinicians. However, the main challenge is to persuade adequate numbers of AN patients to participate in research trials.

摘要

背景

目前对于使用非典型抗精神病药物治疗神经性厌食症（AN）的价值存在不同意见。

目的

评估非典型抗精神病药物在 AN 中的应用文献。

方法

对所有在 2009 年 9 月之前发表的涉及使用非典型抗精神病药物治疗 AN 患者的研究和临床指南进行了综述。分析方法为叙述性综合。

结果

共发现 43 篇出版物或研究方案，包括 4 项随机对照试验、5 项开放标签试验和 26 项病例报告。研究最多的药物是奥氮平、喹硫平和利培酮。非典型抗精神病药物似乎是安全的，并且有一些证据表明它们对抑郁症、焦虑症和核心饮食障碍性精神病学在神经性厌食症患者中有积极作用。目前尚无足够证据证实非典型抗精神病药物在这种情况下能促进体重增加。